Articles tagged with Chemotherapy
Researchers at MIT have developed a new approach to treat cancer by combining chemotherapy, tumor injury, and immunotherapy. In mouse studies, the treatment eliminated tumors completely in nearly half of the mice and showed promise against various types of cancer.
Researchers identified ALRs as key genetic factors influencing treatment response to radiation and chemotherapy. Cells deficient in ALRs are more resistant to radiation and chemotherapy, while those with higher ALR levels are more sensitive.
A peptide-drug conjugate called CBX-12 has been shown to enhance the efficacy of immune checkpoint inhibitors in preclinical cancer models by targeting the acidic environment of cancer cells. The treatment exhibited significantly delayed tumor growth, improved survival, and complete tumor regressions compared to immunotherapy alone.
A study found that chronic stress, measured by allostatic load, was associated with a lower likelihood of completing chemotherapy and lower overall survival rate in patients with lymph node-positive or high-risk lymph node-negative HER2-negative breast cancer. Allostatic load may be a better predictor than genetic ancestry for chemothe...
Researchers found that a cancer chemotherapy drug can restore memory and cognitive function in mice with Alzheimer’s disease by inhibiting blood vessel growth. The study suggests repurposing approved anti-cancer drugs as treatments for Alzheimer’s disease, potentially shortening clinical development time.
A study published in JAMA Oncology found that the type of cancer treatment affects the vaccine response, with chemotherapy resulting in lower antibody levels. Vaccination is still recommended for cancer patients, but optimal protection requires ongoing measures.
Researchers found that cancer patients on chemotherapy had a lower immune response to the first two doses of the Pfizer-BioNTech COVID-19 vaccine. However, a third dose significantly boosted their immune response, reaching levels similar to those of healthy adults after two doses.
A City of Hope clinical trial showed that patients over 65 experiencing significantly fewer treatment-related side effects when a multidisciplinary team analyzed each case and introduced personalized interventions. The completion of advance directives was also higher in the experimental group.
Scientists at Temple University will explore the therapeutic potential of KLS-13019, a CBD analog that shows promise as an opioid alternative. The Phase 2 SBIR grant aims to test the compound's effects on rat models of neuropathic pain, shedding light on its safety and efficacy.
Researchers discovered a combination of two drugs can reduce inflammation following chemotherapy, preventing metastasis in pancreatic and liver cancer. The treatment targets the sEH and EP4 pathways, modulating inflammation to resolve cytokine storms.
Patients with certain gene mutations are at high risk of fatal chemotherapy toxicity, with a 25-times increased risk detected in those with uncommon DPYD variants. The study suggests that adding pre-treatment screening may help prevent avoidable deaths without interrupting standard care.
The KEYNOTE-826 study found that adding immunotherapy to standard first-line treatment increases overall survival by eight months for patients with recurrent, persistent or metastatic cervical cancer. The addition of pembrolizumab to chemotherapy also reduced the risk of death and disease progression by 33%.
A study at ESMO Congress 2021 highlights the need for improved cancer follow-up care to address burdensome symptoms like fatigue. Patients often receive inadequate support, leading to widespread dissatisfaction.
A phase II trial found that high-dose cytarabine followed by pembrolizumab improved cancer remission rates in AML patients, with a complete remission rate of 38%. The treatment also showed promise for patients who had not benefited from standard therapy.
A new study found that young children with cancer are at a higher risk of permanent hearing loss due to the chemotherapy drug cisplatin. The study, published in the journal CANCER, reveals that up to 75% of children under 5 years old experienced hearing loss after treatment.
A new study reports that chemotherapy plus immunotherapy before surgical removal reduces tumor invasiveness in muscle-invasive bladder cancer. In the phase II clinical trial, nearly 25% of bladder cancers were found to be invasive, and surgery often had limited success due to microscopic cancer cell spread.
Despite its promise, cancer immunotherapy faces several hurdles, including limited efficacy and variable outcomes. Researchers are exploring new therapeutic targets and combination strategies to overcome resistance and improve patient outcomes.
A modified chemotherapy regimen for Burkitt lymphoma has been developed, combining CODOX-M and IVAC with rituximab, to reduce toxicity and improve survival rates. The study found a higher overall survival rate and lower frequency of severe side effects compared to standard regimens.
Researchers have identified a new potential treatment for neuroblastoma by targeting the ALT mechanism, which is responsible for chemotherapy resistance. The study found that activating ATM kinase at telomeres promotes chemotherapy resistance in ALT neuroblastoma and suggests a cancer-specific approach to treating this disease.
Researchers identified DSS1 as a critical protein in breast cancer progression and found that depleting it makes cancer cells more responsive to lower doses of anti-cancer drugs. This technique may reduce drug-induced side effects in breast cancer patients, providing a safer treatment option.
Researchers at the University of Huddersfield have developed a new approach to combat cancer treatment challenges by creating self-assembled drugs with high specificity towards human cancer cells. The breakthrough demonstrates unprecedented anti-cancer activity and selectivity in laboratory testing.
Researchers developed a nanotherapeutic platform that combines camptothecin with immune checkpoint inhibitors to increase effectiveness against aggressive tumors. The approach showed promising results in eliminating difficult-to-treat late-stage metastatic colorectal cancer and melanoma tumors.
Scientists investigated a method to enhance immunotherapy for lung cancer and found that combining it with certain chemotherapy drugs could eliminate harmful immune cells. This approach showed promising results in preclinical studies, inducing the regression of about 70% of tumors.
Researchers at SMU found that decreasing TIGAR protein levels in cervical cancer cells makes them more responsive to chemotherapy drugs at low doses. This discovery offers a potential new treatment approach for HPV-induced cervical cancer with fewer side effects.
Researchers found that pre-treatment T2-weighted MRI texture features can accurately predict the response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. The study identified 7 significant texture features and achieved high classification accuracy using a k-nearest neighbor model.
Research has found that cancer cells develop resistance to platinum-based cytotoxic drugs by altering their communication with the surrounding extracellular matrix. This change allows the cancer cells to withstand the damage caused by the treatment and survive the chemotherapeutic attack.
A big data study from UNSW Sydney found that Australian cancer patients kept up their pharmaceutical treatments during last year's COVID-19 lockdowns. The researchers attribute the good news to relatively low rates of COVID-19 infections in Australia, which minimally impacted cancer treatment patterns.
A world-first study found that cancer patients receiving chemotherapy intravenously have more than double the risk of developing a blood clot or thrombosis if the vein is too small and the catheter occupies more than 45% of the vein. Researchers identified specific limits on catheter-to-vein ratios to reduce risks for cancer patients.
A genetic variant in the TCERG1L gene has been identified as a risk factor for cisplatin-induced hearing loss in children with cancer, increasing the risk by three times. The finding could lead to predictive tests to inform treatment decisions and advance pediatric cancer care.
Researchers found thiopurine-induced mutations in leukemia cells, inactivating a DNA repair process and making the cancer resistant to multiple chemotherapy drugs. This study provides direct genomic evidence of chemotherapy-induced drug resistance mutations in pediatric cancer.
A clinical trial in Malawi showed a five-drug combination chemotherapy provided curative benefit for people diagnosed with lymphoma, compared to current standard-of-care-therapy. The treatment was also found to be cost-effective, preventing more than seven disability-adjusted life years at a lower cost per DALY prevented.
A study published by The BMJ found that remote 24-hour monitoring for cancer patients receiving chemotherapy significantly reduces symptom burden, anxiety, and work limitations. Patients who used the system experienced improved quality of life and reduced supportive care needs.
The study found that cancer cells become less stiff after exposure to chemotherapy drugs, but the rate of stiffness change decreases under hypoxic conditions. Alteration in cytoskeletal structure influences overall cell functions, including signaling, communication, adhesion, transport, and tumor metastasis.
The investigational therapy ficlatuzumab, targeting the extracellular hepatocyte growth factor (HGF), showed clinical efficacy in patients with relapsed/refractory acute myeloid leukemia. A 53% complete response rate was observed, with improved progression-free and overall survival rates.
Researchers at IMIM-Hospital del Mar and CIBERONC discover a low-toxicity treatment combining chemotherapy and BRAF inhibitors eradicates malignant melanoma by preventing DNA repair. The strategy offers a new therapeutic perspective for patients with BRAF oncogene mutations.
Researchers have developed a new type of nanocarrier that combines photothermal, chemo-therapy, and chemodynamic therapy to target and destroy cancer cells. The nanoclusters, which are responsive to near-infrared light, show a significant inhibitory effect on mouse tumor growth in vivo experiments.
Hematopoietic stem cells use RNA from junk DNA to enhance activation after chemotherapy, leading to increased inflammatory signaling and faster blood cell production. This mechanism helps improve blood regeneration after chemotherapy.
Researchers at Queen Mary University of London have discovered that immune cells can be stimulated to assemble into special structures within pancreatic cancer, improving the efficacy of chemotherapy. The findings suggest a potential therapeutic strategy for promoting an anti-tumour immune response in patients.
A meta-analysis found that obese patients with colorectal cancer receive lower cumulative doses of adjuvant chemotherapy relative to their body surface area than non-obese patients. This may explain the poorer survival rates observed in obese patients receiving adjuvant chemotherapy for colorectal cancer. The study suggests that obese ...
A meta-analysis of pediatric patients treated with medical cannabis found the treatment to be successful in reducing seizures and nausea in children undergoing chemotherapy, while also noting potential negative effects on mental health, including fatigue and lethargy.
A new study establishes a more tolerable chemotherapy regimen for children with high-risk neuroblastoma, while maintaining its effectiveness. The European Neuroblastoma Study Group's rCOJEC regimen showed significant reductions in side effects compared to the US-based MSKCC-N5 regimen.
Researchers found that PrimPol helps cells survive chemotherapy damage by facilitating DNA repair; repressing this protein could make tumor cells more sensitive to cancer treatments. This discovery has implications for Fanconi anaemia, a rare disease with few therapeutic options.
A new study published in Proceedings of the National Academy of Sciences suggests that surgery should precede chemotherapy for certain patients with ovarian cancer. The research used a mathematical model to examine treatment outcomes and found that complete debulking surgery followed by chemotherapy provides better results. For patient...
Researchers at Washington University in St. Louis have developed a predictive model using tumor biomarkers and imaging parameters to forecast chemotherapy response. The model's accuracy reaches 0.94, allowing for early adjustments to treatment plans and reduced use of toxic chemotherapy drugs.
Scientists found that platinum chemotherapy can cause genetic changes in children with neuroblastoma, leading to increased risk of secondary leukemia. The study's findings could lead to identifying high-risk children and tailoring their treatment plans to reduce this risk.
Researchers at the University of Copenhagen conducted a study on stem cell transplantation, revealing that one drug is more effective than previously thought due to its impact on cell signaling pathways. This discovery may lead to improved drugs for both stem cell mobilization and HIV treatment.
The ECOG-ACRIN Cancer Research Group presented new research results on patients with breast and HPV-associated throat cancers. A phase III trial found platinum chemotherapy ineffective in preventing recurrence of basal-like triple-negative breast cancer, while a study on severe joint pain in postmenopausal women with hormone receptor-p...
Researchers from NUS Cancer Science Institute have discovered a link between high levels of DNA repair protein RAD51 and platinum chemotherapy resistance in ovarian cancer patients. This finding could help identify patients who may require novel immunotherapy approaches to improve treatment outcomes.
A Northwestern University study found that specific types of gut bacteria can protect other good bacteria from cancer treatments. By metabolizing chemotherapy drugs, these protective bacteria can temper short- and long-term side effects of treatment, potentially leading to new dietary supplements or probiotics.
Researchers from South Ural State University and the Russian Academy of Sciences have synthesized six new acetylthioglycoside derivatives with potential anti-cancer effects. The compounds are based on a dithiolothionic cycle, which releases hydrogen sulfide, carbon monoxide, and nitric oxide.
Researchers have developed a new technique using chemically-sensitive soft X-rays to analyze the internal structure, chemistry and environmental behavior of organic nanocarriers. This non-disruptive method allows for detailed analysis of nanocarrier properties, including their size, water-content and response to changing environments.
Decitabine, used to treat blood cancers like MDS and AML, works by activating endogenous retroviruses that induce an immune response. The study found two key gene sequences involved in this process, Staufen1 and TINCR, whose expression levels determine a patient's response to the drug.
Research found that treatments with 6-mercaptopurine and/or 5-azacitidine do not reverse epithelial-to-mesenchymal transition, but instead sensitize cancer cells to chemotherapeutic drugs. This approach has potential for inhibiting highly resistant triple-negative breast cancer cells.
Chemists create supramolecular cage using Pd6(TPT)4 cages that can transport and release pharmaceutically active molecules like ibuprofen and progesterone. The system uses ultrasonification to break the bonds, releasing the drugs at the desired location.
Researchers have discovered that nanoparticles containing chemotherapy drug Capecitabine can attach to diseased cells, bypassing healthy ones and reducing toxic side effects. This targeted delivery system has shown promising results in animal experiments, improving cancer treatment outcomes.
Researchers identified DUSP16 as a protein that promotes chemotherapy resistance in four types of cancer. Elevated DUSP16 levels can lead to reduced treatment effectiveness, highlighting its potential use as a biomarker for sensitivity to chemotherapy.
Researchers at Massachusetts General Hospital develop a new radiation technique that carefully targets tumors while sparing surrounding tissues, reducing inflammation and preserving swallowing function. The study shows promising results in patients with localized lung cancer, with none developing severe esophagitis despite high-dose ra...
Nagoya University researchers discovered a molecular pathway that enhances chemotherapy resistance in some pancreatic cancer patients. Targeting the taurine upregulating gene 1 (TUG1) RNA could improve patient response to therapy and increase overall survival.
Researchers from Northwestern University develop technology allowing microbes to produce drugs with self-regulating feedback control systems, improving reaction conditions and product yield. The innovation has vast implications for producing other drugs and products, potentially making therapeutics more accessible.
A global phase 3 clinical study confirms the effectiveness of targeted antibody drug conjugates against refractory metastatic triple-negative breast cancer. The ADC drug sacituzumab govitecan delivered a high dose of a cancer-killing drug to tumor cells, improving progression-free and overall survival.